HRT in 2026: What's Changed Since the WHI Study

Few topics in women's health have generated as much confusion, fear, and misinformation as hormone replacement therapy. For over two decades, millions of women have avoided or discontinued HRT based on headlines from a single study that was later found to have been widely misinterpreted.

In 2025 and 2026, the landscape shifted significantly. Regulatory changes, updated guidelines, and a growing body of reanalyzed data have reshaped the conversation. Here's where things stand.

What happened with the WHI, and what went wrong

The Women's Health Initiative (WHI) was a large randomized controlled trial that began in 1993 and reported its first results in 2002. When the combined estrogen-plus-progestin arm was stopped early due to an increase in breast cancer events, the headlines were immediate and dramatic: hormone therapy causes breast cancer and heart disease.

Prescriptions dropped by more than 50% almost overnight. An entire generation of women was told that HRT was dangerous, full stop.

But the story was far more nuanced than the headlines suggested. Several critical details were lost in the public response:

• The average age of participants was 63. Most women had been postmenopausal for over a decade before starting hormones. This is not when most women use HRT, or when it's currently recommended.
• The study used a specific formulation. Oral conjugated equine estrogens (Premarin) plus medroxyprogesterone acetate (Provera). Different formulations, routes, and types of progestogen carry different risk profiles.
• The estrogen-only arm told a different story. Women who took estrogen alone (because they'd had a hysterectomy) actually showed a trend toward reduced breast cancer risk and reduced coronary heart disease. This result received far less attention.
• The absolute risk increase was small. The increased breast cancer risk amounted to fewer than 1 additional case per 1,000 women per year. This was a statistically significant relative risk but a small absolute one.

The timing hypothesis: when you start matters

Perhaps the most important finding to emerge from post-WHI research is the "timing hypothesis," also called the "window of opportunity." Multiple analyses, including WHI subgroup data, the Danish Osteoporosis Prevention Study, and the ELITE trial, have converged on the same conclusion: the effects of hormone therapy depend critically on when it's started relative to menopause.

When initiated within 10 years of menopause or before age 60, hormone therapy is associated with:

• Reduced all-cause mortality
• Reduced coronary heart disease events
• Improved bone density and reduced fracture risk
• Effective relief of vasomotor symptoms (hot flashes, night sweats)
• Improvement in genitourinary symptoms

When started more than 10 years after menopause or after age 60, the risk-benefit profile shifts. This is consistent with the theory that estrogen is protective for healthy blood vessels but may be harmful to vessels that have already developed significant atherosclerosis.

The FDA's 2025 decision: black-box warning removed

In November 2025, the FDA removed the black-box warning from systemic estrogen therapy products. The black-box warning, the most serious type of FDA safety warning, had been in place since 2003 and was a direct consequence of the WHI results.

The FDA's decision was based on a comprehensive review of evidence accumulated over two decades, including the WHI's own long-term follow-up data, which showed that the initial risk concerns were more complex than originally reported. The 20-year follow-up of the WHI estrogen-only arm actually showed reduced breast cancer mortality in the treatment group.

The removal of the black-box warning does not mean that HRT is risk-free. It means the FDA concluded that the previous warning overstated the risks for the population most likely to use hormone therapy: younger, recently menopausal women with moderate to severe symptoms.

Current NAMS guidelines

The North American Menopause Society (NAMS), the leading professional organization for menopause research and clinical practice, updated its position statement to reflect the evolving evidence. The current recommendations include:

• Hormone therapy remains the most effective treatment for vasomotor symptoms and genitourinary syndrome of menopause
• For women under 60 or within 10 years of menopause onset, the benefits of HRT generally outweigh the risks for those with moderate to severe symptoms
• Transdermal estrogen (patches, gels) is preferred over oral estrogen because it avoids the first-pass liver metabolism that increases clotting risk
• Micronized progesterone is preferred over synthetic progestins for endometrial protection, based on a more favorable safety profile
• The lowest effective dose for the shortest appropriate duration remains the guiding principle, but there is no mandatory time limit for use
• Individual risk assessment should drive decision-making, not blanket age or duration cutoffs

The estrogen patch shortage

One of the most tangible consequences of the shifting HRT landscape has been a surge in demand for transdermal estrogen products. Since the FDA's black-box warning removal and growing public awareness of updated guidelines, prescriptions for estrogen patches have increased substantially.

This has created supply chain challenges. As of early 2026, several major estrogen patch brands have experienced intermittent shortages, with some patients facing weeks-long waits for refills. The shortage has pushed some patients toward compounded hormone products or oral formulations, which may carry different risk profiles.

Manufacturers have reported scaling up production, but the gap between supply and demand has highlighted how decades of undertreated menopause created pent-up demand that the pharmaceutical supply chain was unprepared to meet.

Who benefits most from HRT

Based on current evidence, the women who stand to benefit most from hormone therapy include:

• Women with moderate to severe hot flashes and night sweats that affect quality of life, sleep, or daily functioning
• Women who experienced premature or early menopause (before age 40 or 45), who face increased risks from prolonged estrogen deprivation
• Women at elevated risk for osteoporosis who cannot tolerate other bone-protective medications
• Women with genitourinary syndrome of menopause (vaginal dryness, painful intercourse, urinary symptoms) that doesn't respond to local treatments alone

Risks that remain

Updated evidence has not eliminated all concerns. Important risks persist and should be part of any informed discussion with a healthcare provider:

Breast cancer

Combined estrogen-progestogen therapy (for women with a uterus) is still associated with a small increase in breast cancer risk with prolonged use, typically beyond 5 years. The risk appears to be lower with micronized progesterone compared to synthetic progestins, and the estrogen-only regimen (for women without a uterus) may not increase breast cancer risk at all. However, the data are not conclusive enough to eliminate this concern entirely.

Blood clots

Oral estrogen increases the risk of venous thromboembolism (blood clots). This risk is substantially lower with transdermal formulations, which is one reason patches and gels are now preferred. Women with a personal or strong family history of blood clots may need to avoid oral estrogen or use non-oral routes.

Stroke

Oral estrogen is associated with a small increase in ischemic stroke risk. Again, transdermal estrogen appears to carry a lower risk. This is particularly relevant for women with pre-existing stroke risk factors.

Individual variation

Not every woman responds the same way to hormone therapy. Genetic factors, baseline health status, body composition, and other variables all influence the risk-benefit calculation. This is why personalized assessment with a knowledgeable provider is essential.

The bottom line

The HRT landscape in 2026 looks dramatically different from 2002. The evidence now supports a far more nuanced view: hormone therapy is not universally dangerous, nor is it universally appropriate. For many women, particularly those in early menopause with significant symptoms, the benefits clearly outweigh the risks. For others, the calculation may be different.

What hasn't changed is the importance of making an informed, individualized decision with a provider who understands the current evidence. The decades of fear and avoidance left many women undertreated. The correction is underway, but it requires both patients and providers to engage with the complexity of the data rather than defaulting to outdated conclusions.